Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Best Peptides for Postpartum Recovery: Mechanism Comparison

BPC-157 Upregulates VEGF, promotes fibroblast migration, accelerates collagen deposition Soft tissue repair in pelvic floor, abdominal wall (diastasis recti), perineal tears 250–500 mcg twice daily subcutaneously for 4–6 weeks Strong preclinical data in tendon

This comparison does not assign a generated winner or score.

  • BPC-157
  • Upregulates VEGF, promotes fibroblast migration, accelerates collagen deposition
  • Soft tissue repair in pelvic floor, abdominal wall (diastasis recti), perineal tears
  • 250–500 mcg twice daily subcutaneously for 4–6 weeks
  • Strong preclinical data in tendon/ligament healing; no direct postpartum trials
  • Best choice for structural tissue damage from delivery. Mechanism directly addresses connective tissue repair
  • Thymalin
  • Thymic peptide bioregulator; restores T-cell maturation, normalizes Th1/Th2 balance
  • Immune system restoration after pregnancy-induced suppression
  • 10 mg daily × 10 days, subcutaneous; repeat after 20-day break if needed
  • Clinical trials show CD4+ normalization in immunocompromised patients within 28 days
  • Targets the specific immune dysfunction pregnancy causes. Evidence stronger than BPC-157 for this pathway
  • MK-677 (Ibutamoren)
  • Ghrelin receptor agonist; stimulates endogenous GH release, preserves pulsatile secretion
  • Metabolic recovery, lean mass restoration, insulin sensitivity normalization
  • 10–25 mg once daily before bed, oral administration
  • Phase II trials show 1.8 kg lean mass gain over 12 weeks; improves insulin sensitivity
  • Oral administration is practical advantage; evidence for metabolic outcomes solid but requires 8–12 weeks
  • Ipamorelin
  • Selective GH secretagogue; stimulates somatotrophs without affecting cortisol or prolactin
  • Similar to MK-677 but with cleaner receptor profile (no prolactin spike)
  • 200–300 mcg once daily subcutaneously before bed
  • Limited human data; mechanism well-understood from growth hormone pharmacology
  • Preferable to MK-677 if prolactin elevation is a concern during breastfeeding
More references

Related material